

# Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants

**Xspray Pharma has received written declarations of intent whereby owners of approximately 50 percent of shares in the company state their intent to exercise warrants TO6 to subscribe for newly issued shares during the subscription period 18 April – 2 May 2024 for the subscription price 40.00 SEK per share.**

“We are very pleased over the continued confidence from our largest shareholders. We are hopeful to gain a high degree of subscription for TO6 warrants and that we thereby ensure necessary financing of our commercialization plan,” says Per Andersson, CEO of Xspray Pharma.

The outstanding warrants TO6 were allotted as part of the units that were subscribed for in connection to the preferential rights issue that Xspray Pharma made in June 2023. If all outstanding TO6 warrants are exercised, the company receives SEK 125.5 million in gross proceeds. The declarations of intent are expected to lead to the exercise of approximately 50 percent of the outstanding warrants of series TO6. The declarations of intent have been made by Flerie Invest, Ribbskottet AB, Fjärde AP-fonden, Andra AP-fonden, Unionen and Tredje AP-fonden.

## **For further information, please contact:**

---

Kerstin Hasselgren  
Senior Advisor & Investor Relations  
Xspray Pharma AB  
Mob: +46 (0) 70 311 16 83  
E-mail: kerstin.hasselgren@xspray.com

## **About Xspray Pharma**

### **About Xspray Pharma AB**

Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit [www.xspraypharma.com](http://www.xspraypharma.com).

*This information is information that Xspray Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-10 10:00 CEST.*

**Attachments**

---

[Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants](#)